Cancer research growth in India has been inconsistent. A new study reveals clinical trials are concentrated in high-income nations. Low and...

Administering oral doses of the antibiotic azithromycin to pregnant individuals could potentially serve as a cost-effective measure for mit...

The mRNA-based vaccine was developed by Gennova Biopharmaceuticals using the indigenous platform technology, and supported under the Missio...

Researchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people.

Earlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world's first intranasal COVID-19 vaccine, has received approva...

The Phase III trial results of Hetero's Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CR...

The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...

Hetero Labs and Optimus Pharma had approached the drug regulatory authority last month seeking waivers from conducting local trials. Howeve...

The SEC asked the companies to conduct bioavailability and bioequivalence (BA/BE) studies and submit safety data at its meeting on Friday, ...

Dr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...

The drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...

The company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

Merck or Merck Sharpe Dohme (MSD), the innovator, has already issued a voluntary licence to these companies to manufacture and supply Molnu...

The move comes as the Indian government thinks that it has sufficient doses of vaccine for its population and can also supply to other nati...

The training programme which will extend for about six to eight weeks will see participation of investigators, epidemiologists, clinicians ...

Poonawalla said the company plans to make 70 million doses per month and increase this to 100 million. These will be used for phase 3 clini...